Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.

Sara Elena Rebuzzi,Sebastiano Buti,Andrea Sbrana,Giuseppe Procopio,Ugo De Giorgi,Maria Giuseppa Vitale,Francesco Massari,Daniele Santini,Alessia Cavo,Giuseppe Luigi Banna,Mariella Sorarů,Alessio Cortellini,Marco Messina,Valentino Martelli,Veronica Mollica,Marco Stellato,Helga Lipari,Fabio Catalano,Alessio Signori,Giuseppe Fornarini

Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.

2020

751Background: Biomarkers to select mRCC patients most likely to benefit to immune-checkpoint inhibitors are still needed. The ongoing retrospective multicentre Meet-URO 15 (I-BIO-REC) study evalua...

Keywords:

Lymphocyte
Oncology
Monocyte
Nivolumab
Pathology
Systemic inflammation
Internal medicine
Renal cell carcinoma
Medicine
Biomarker (medicine)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations